Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Hardiono D. Pusponegoro is active.

Publication


Featured researches published by Hardiono D. Pusponegoro.


Acta Paediatrica | 2015

Gluten and casein supplementation does not increase symptoms in children with autism spectrum disorder

Hardiono D. Pusponegoro; Sofyan Ismael; Agus Firmansyah; Sudigdo Sastroasmoro; Yvan Vandenplas

A gluten‐ and casein‐free diet is often given to children with autism spectrum disorder (ASD). We aimed to determine the effect of gluten and casein supplementation on maladaptive behaviour, gastrointestinal symptom severity and intestinal fatty acids binding protein (I‐FABP) excretion in children with ASD.


Pediatric Infectious Disease Journal | 1998

Epidemiologic study of bacterial meningitis in Jakarta and Tangerang: preliminary report.

Hardiono D. Pusponegoro; Hanifah Oswari; Dalima Astrawinata; Veronica Fridawati

OBJECTIVE To identify the cause of bacterial meningitis in children >1 month of age and <5 years of age in several hospitals in Jakarta and Tangerang, Indonesia. METHODS Hospital-based, prospective surveillance study of 100 subjects between 1 month and 5 years of age. Subjects meeting inclusion criteria were evaluated for clinical and laboratory findings of bacterial meningitis. RESULTS Of 16 subjects enrolled thus far, 11 have been diagnosed as bacterial meningitis. Of these 11, 6 had positive cerebrospinal fluid (CSF) cultures (2 with Haemophilus influenzae and one each with Neisseria meningitidis, Staphylococcus aureus, Klebsiella ozaenae and Escherichia coli). Three of the 6 had positive latex agglutination tests (LAT; 2 H. influenzae and 1 N. meningitidis); LAT was negative for all 10 with negative CSF culture. CSF Gram-stained smear was positive only for the subject with E. coli. CONCLUSIONS The number of children admitted with bacterial meningitis has been declining, perhaps because of early treatment with antibiotics in the community. Of culture-positive cases 33% have been caused by H. influenzae, but this result is based on few patients thus far. LAT has correlated well with culture, whereas Gram stain has had low sensitivity, perhaps reflecting deficiencies in technique.


Pediatric Gastroenterology, Hepatology & Nutrition | 2015

Maladaptive Behavior and Gastrointestinal Disorders in Children with Autism Spectrum Disorder

Hardiono D. Pusponegoro; Sofyan Ismael; Sudigdo Sastroasmoro; Agus Firmansyah; Yvan Vandenplas

Purpose Various gastrointestinal factors may contribute to maladaptive behavior in children with autism spectrum disorders (ASD). To determine the association between maladaptive behavior in children with ASD and gastrointestinal symptoms such as severity, intestinal microbiota, inflammation, enterocyte damage, permeability and absorption of opioid peptides. Methods This observational cross-sectional study compared children with ASD to healthy controls, aged 2-10 years. Maladaptive behavior was classified using the Approach Withdrawal Problems Composite subtest of the Pervasive Developmental Disorder Behavior Inventory. Dependent variables were gastrointestinal symptom severity index, fecal calprotectin, urinary D-lactate, urinary lactulose/mannitol excretion, urinary intestinal fatty acids binding protein (I-FABP) and urinary opioid peptide excretion. Results We did not find a significant difference between children with ASD with severe or mild maladaptive behavior and control subjects for gastrointestinal symptoms, fecal calprotectin, urinary D-lactate, and lactulose/mannitol ratio. Urinary opioid peptide excretion was absent in all children. Children with ASD with severe maladaptive behavior showed significantly higher urinary I-FABP levels compared to those with mild maladaptive behavior (p=0.019) and controls (p=0.015). Conclusion In our series, maladaptive behavior in ASD children was not associated with gastrointestinal symptoms, intestinal inflammation (no difference in calprotectin), microbiota (no difference in urinary D-lactate) and intestinal permeability (no difference in lactulose/manitol ratio). ASD children with severe maladaptive behavior have significantly more enterocyte damage (increased urinary I-FABP) than ASD children with mild maladaptive behavior and normal children.


Scientific Programming | 2017

Jadwal Imunisasi Anak Usia 0 – 18 tahun Rekomendasi Ikatan Dokter Anak Indonesia 2017

Hartono Gunardi; Cissy B. Kartasasmita; Sri Rezeki Hadinegoro; Hindra Irawan Satari; Soedjatmiko Soedjatmiko; Hanifah Oswari; Hardiono D. Pusponegoro; Jose Rl Batubara; Arwin Ap Akib; Badriul Hegar; Piprim B. Yanuarso; Toto Wisnu Hendrarto

Ikatan Dokter Anak Indonesia melalui Satuan Tugas Imunisasi mengeluarkan rekomendasi Imunisasi IDAI tahun 2017 untuk menggantikan jadwal imunisasi sebelumnya. Jadwal imunisasi 2017 ini bertujuan menyeragamkan jadwal imunisasi rekomendasi IDAI dengan jadwal imunisasi Kementerian Kesehatan RI khususnya untuk imunisasi rutin. Jadwal imunisasi 2017 juga dibuat berdasarkan ketersediaan kombinasi vaksin DTP dengan hepatitis B seperti DTPw-HB-Hib, DTPa-HB-Hib-IPV, dan dalam situasi keterbatasan atau kelangkaan vaksin tertentu seperti vaksin DTPa atau DTPw tanpa kombinasi dengan vaksin lainnya. Hal baru yang terdapat pada jadwal 2017 antara lain: vaksin hepatitis B monovalen tidak perlu diberikan pada usia 1 bulan apabila anak akan mendapat vaksin DTP-Hib kombinasi dengan hepatitis B; bayi paling sedikit harus mendapat satu dosis vaksin IPV (inactivated polio vaccine) bersamaan (simultan) dengan OPV-3 saat pemberian DTP-3; vaksin DTPw direkomendasikan untuk diberikan pada usia 2,3 dan 4 bulan. Hal baru yang lain adalah untuk vaksin influenza dapat diberikan vaksin inaktif trivalen atau quadrivalen, vaksin MMR dapat diberikan pada usia 12 bulan apabila anak belum mendapat vaksin campak pada usia 9 bulan. Vaksin HPV apabila diberikan pada remaja usia 10-13 tahun, pemberian cukup 2 dosis dengan interval 6-12 bulan; respons antibodi setara dengan 3 dosis. Vaksin Japanese Encephalitis direkomendasikan untuk diberikan mulai usia 12 bulan pada daerah endemis atau pada turis yang akan bepergian ke daerah endemis. Vaksin dengue direkomendasikan untuk diberikan pada anak usia 9-16 tahun dengan jadwal 0, 6, dan 12 bulan. Dengan pemberian imunisasi sesuai rekomendasi, diharapkan anak-anak Indonesia terlindungi dari penyakit infeksi yang dapat dicegah dengan imunisasi.


Paediatrica Indonesiana | 2016

Rett syndrome in childhood: the clinical characteristics

E S Herini; Irawan Mangunatmadja; Purboyo Solek; Hardiono D. Pusponegoro

The prevalence rate of RS in various coun- tries is from 1:10,000 to 1:23,000 female live births. RS is most often misdiagnosed as autism, cerebral palsy, or non-specific developmental de- lay. While many health professionals may not be familiar with RS, it is a relatively frequent cause of neurological dysfunction in females. There are no biological markers for this disease, the diagno- sis is established by history taking and clinical find- ings. We reported two patients, both girls, with RS.


Scientific Programming | 2007

Perbandingan Efektivitas Pengobatan Lorazepam Bukal Dengan Diazepam Rektal dalam Tata Laksana awal Kejang pada Anak

Susiana Tendean; Hardiono D. Pusponegoro; Bambang Madiyono

Latar belakang. Lorazepam bukal dan diazepam rektal digunakan dalam tata laksana inisial kejang pada anak. Penelitian yang membandingkan efektivitas penggunaan lorazepam bukal dan diazepam rektal sejauh ini belum pernah dilakukan pada anak di Indonesia. Tujuan. Untuk mengevaluasi efektivitas pengobatan lorazepam bukal dibandingkan diazepam rektal dalam tata laksana inisial kejang pada anak. Metoda. Penelitian ini adalah uji klinis acak terbuka pada anak kejang berusia 6 bulan– 6 tahun, sebelum mendapat obat antikonvulsan untuk menghentikan kejang. Subyek penelitian menerima lorazepam bukal atau diazepam rektal berdasarkan randomisasi. Parameter keberhasilan terapi adalah kemampuan obat untuk menghentikan kejang tanpa efek samping yang berarti dan kecepatan obat menghentikan kejang. Efek samping diobservasi setelah pemberian obat. Hasil. Lorazepam bukal efektif menghentikan kejang pada 18 dari 22 pasien, sedangkan diazepam rektal efektif menghentikan kejang pada 20 dari 22 pasien. Pada penelitian ini didapatkan efektivitas lorazepam bukal sama dengan diazepam rektal (p = 0,664; 95% IK 0,71 – 1,14). Diazepam rektal lebih cepat dalam menghentikan kejang (44,7 ± 22,1 detik) dibandingkan lorazepam bukal (92,2 ± 53,5 detik), perbedaan ini secara statistik bermakna (p = 0,002). Tidak dijumpai efek samping akibat pemakaian lorazepam bukal maupun diazepam rektal. Kesimpulan. Lorazepam bukal dan diazepam rektal mempunyai efektivitas yang sama dalam mengatasi kejang namun diazepam rektal lebih cepat menghentikan kejang dibandingkan lorazepam bukal.


Paediatrica Indonesiana | 2009

Quality of home stimulation and language development in children aged 12-24 months living in orphanages and family homes

Yuridyah P. Mulyadi; Soedjatmiko Soedjatmiko; Hardiono D. Pusponegoro


Pediatrics and Neonatology | 2016

Gross Motor Profile and Its Association with Socialization Skills in Children with Autism Spectrum Disorders

Hardiono D. Pusponegoro; Pustika Efar; Soedjatmiko; Amanda Soebadi; Agus Firmansyah; Hui-Ju Chen; Kun-Long Hung


Paediatrica Indonesiana | 2013

Acute kidney injury in asphyxiated neonates

Roy Amardiyanto; Partini Pudjiastuti Trihono; Lily Rundjan; Hardiono D. Pusponegoro


Paediatrica Indonesiana | 2016

Brainstem auditory evoked potentials in children with microcephaly

Irawan Mangunatmadja; Dwi Putro Widodo; Hardiono D. Pusponegoro

Collaboration


Dive into the Hardiono D. Pusponegoro's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Lily Rundjan

University of Indonesia

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge